Income Tax Expense (Benefit) in USD of Emmaus Life Sciences, Inc. from Q2 2010 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Emmaus Life Sciences, Inc. quarterly/annual Income Tax Expense (Benefit) history and change rate from Q2 2010 to Q3 2025.
  • Emmaus Life Sciences, Inc. Income Tax Expense (Benefit) for the quarter ending 30 Sep 2025 was $579K.
  • Emmaus Life Sciences, Inc. Income Tax Expense (Benefit) for the twelve months ending 30 Sep 2025 was -$1K, a 98.9% increase year-over-year.
  • Emmaus Life Sciences, Inc. annual Income Tax Expense (Benefit) for 2024 was $29K.
  • Emmaus Life Sciences, Inc. annual Income Tax Expense (Benefit) for 2023 was -$59K, a 198% decline from 2022.
  • Emmaus Life Sciences, Inc. annual Income Tax Expense (Benefit) for 2022 was $60K, a 140% increase from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Change (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Change (%)

Emmaus Life Sciences, Inc. Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$1K $579K +$580K 01 Jul 2025 30 Sep 2025 10-Q 14 Nov 2025
Q2 2025 -$581K -$590K -$621K -2003% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025
Q1 2025 $40K $4K +$11K 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025
Q4 2024 $29K $6K +$118K 01 Oct 2024 31 Dec 2024 10-K 14 Apr 2025
Q3 2024 -$89K -$1K -$39K -103% 01 Jul 2024 30 Sep 2024 10-Q 14 Nov 2025
Q2 2024 -$50K $31K +$65K 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025
Q1 2024 -$115K -$7K -$56K -114% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025
Q4 2023 -$59K -$112K -$128K -800% 01 Oct 2023 31 Dec 2023 10-K 14 Apr 2025
Q3 2023 $69K $38K +$73K 01 Jul 2023 30 Sep 2023 10-Q 19 Nov 2024
Q2 2023 -$4K -$34K -$216K -119% 01 Apr 2023 30 Jun 2023 10-Q 10 Sep 2024
Q1 2023 $212K $49K +$152K 01 Jan 2023 31 Mar 2023 10-Q 10 Sep 2024
Q4 2022 $60K $16K +$49K 01 Oct 2022 31 Dec 2022 10-K 03 Jul 2024
Q3 2022 $11K -$35K -$267K -115% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023
Q2 2022 $278K $182K +$374K 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023
Q1 2022 -$96K -$103K -$121K -672% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023
Q4 2021 $25K -$33K +$428K +92.8% 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023
Q3 2021 -$403K $232K -$61K -20.8% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$342K -$192K +$307K +61.5% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$649K $18K -$268K -93.7% 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022
Q4 2020 -$381K -$461K -$466K -9320% 01 Oct 2020 31 Dec 2020 10-K 31 Mar 2022
Q3 2020 $85K $293K +$237K +423% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$152K -$499K -$550K -1078% 01 Apr 2020 30 Jun 2020 10-Q 01 Sep 2021
Q1 2020 $398K $286K +$234K +450% 01 Jan 2020 31 Mar 2020 10-Q 01 Sep 2021
Q4 2019 $164K $5K 01 Oct 2019 31 Dec 2019 10-K/A 10 Aug 2021
Q3 2019 $56K 01 Jul 2019 30 Sep 2019 10-Q 26 Aug 2021
Q2 2019 $51K 01 Apr 2019 30 Jun 2019 10-Q 26 Aug 2021
Q1 2019 $52K +$50.1K +2637% 01 Jan 2019 31 Mar 2019 10-Q 26 Aug 2021
Q1 2018 $1.9K -$28.7K -93.8% 01 Jan 2018 31 Mar 2018 10-Q 13 May 2019
Q3 2017 $2.6K -$46.1K 01 Jul 2017 30 Sep 2017 10-K 11 Dec 2018
Q2 2017 $16.3K 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 $30.6K 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018
Q4 2016 $1.8K +$1.5K +500% 01 Oct 2016 31 Dec 2016 10-Q 20 Feb 2018
Q4 2015 $2.1K $300 -$2.9K -90.6% 01 Oct 2015 31 Dec 2015 10-Q/A 30 Mar 2017
Q3 2015 $5K $200 -$600 -75% 01 Jul 2015 30 Sep 2015 10-K 22 Dec 2016
Q2 2015 $5.6K $800 -$1K -55.6% 01 Apr 2015 30 Jun 2015 10-Q 15 Aug 2016
Q1 2015 $6.6K $800 -$200 -20% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 $6.8K $3.2K +$1.6K +100% 01 Oct 2014 31 Dec 2014 10-Q 17 Feb 2016
Q3 2014 $5.2K $800 +$800 01 Jul 2014 30 Sep 2014 10-K 05 Jan 2016
Q2 2014 $4.4K $1.8K +$1.8K 01 Apr 2014 30 Jun 2014 10-Q 14 Aug 2015
Q1 2014 $2.6K $1K +$1K 01 Jan 2014 31 Mar 2014 10-Q 18 May 2015
Q4 2013 $1.6K $1.6K +$800 +100% 01 Oct 2013 31 Dec 2013 10-Q 13 Feb 2015
Q3 2013 $800 $0 +$100 01 Jul 2013 30 Sep 2013 10-K 29 Dec 2014
Q2 2013 $700 $0 -$1.1K -100% 01 Apr 2013 30 Jun 2013 10-Q 14 Aug 2014
Q1 2013 $1.8K $0 $0 01 Jan 2013 31 Mar 2013 10-Q 15 May 2014
Q4 2012 $1.8K $800 -$100 -11.1% 01 Oct 2012 31 Dec 2012 10-Q 13 Feb 2014
Q3 2012 $1.9K -$100 -$100 01 Jul 2012 30 Sep 2012 10-K 23 Dec 2013
Q2 2012 $2K $1.1K +$1.1K 01 Apr 2012 30 Jun 2012 10-Q 14 Aug 2013
Q1 2012 $900 $0 $0 01 Jan 2012 31 Mar 2012 10-Q 15 May 2013
Q4 2011 $900 $900 -$400 -30.8% 01 Oct 2011 31 Dec 2011 10-Q/A 22 Feb 2013
Q3 2011 $1.3K $0 01 Jul 2011 30 Sep 2011 10-K 15 Jan 2013
Q2 2011 $0 $0 01 Apr 2011 30 Jun 2011 10-Q/A 11 Sep 2012
Q1 2011 $0 01 Jan 2011 31 Mar 2011 10-Q 15 May 2012
Q4 2010 $1.3K 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012
Q2 2010 $0 01 Apr 2010 30 Jun 2010 10-Q/A 09 Sep 2011

Emmaus Life Sciences, Inc. Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $29K +$88K 01 Jan 2024 31 Dec 2024 10-K 14 Apr 2025
2023 -$59K -$119K -198% 01 Jan 2023 31 Dec 2023 10-K 14 Apr 2025
2022 $60K +$35K +140% 01 Jan 2022 31 Dec 2022 10-K 03 Jul 2024
2021 $25K +$406K 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023
2020 -$381K -$545K -332% 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022
2019 $164K +$125K +321% 01 Jan 2019 31 Dec 2019 10-K/A 10 Aug 2021
2018 $39K +$36.4K +1400% 01 Jan 2018 31 Dec 2018 10-K 25 Jan 2021
2017 $2.6K +$600 +30% 01 Oct 2016 30 Sep 2017 10-K 11 Dec 2018
2016 $2K -$3K -60% 01 Oct 2015 30 Sep 2016 10-K 29 Dec 2017
2015 $5K -$200 -3.85% 01 Oct 2014 30 Sep 2015 10-K 22 Dec 2016
2014 $5.2K +$4.4K +550% 01 Oct 2013 30 Sep 2014 10-K 05 Jan 2016
2013 $800 -$1.1K -57.9% 01 Oct 2012 30 Sep 2013 10-K 29 Dec 2014
2012 $1.9K +$600 +46.2% 01 Oct 2011 30 Sep 2012 10-K 23 Dec 2013
2011 $1.3K +$500 +62.5% 01 Oct 2010 30 Sep 2011 10-K 15 Jan 2013
2010 $800 01 Oct 2009 30 Sep 2010 10-K 22 Dec 2011
* An asterisk sign (*) next to the value indicates that the value is likely invalid.